ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-1D6126
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Insights Forecast to 2028
BUY CHAPTERS

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Research Report 2025

Code: QYRE-Auto-1D6126
Report
June 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Alexion Pharmaceuticals
RemeGen, Ltd.
Nihon Pharmaceutical
Harbour Biomed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

The global market for Neuromyelitis Optica Spectrum Disorder (NMOSD) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
North American market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Neuromyelitis Optica Spectrum Disorder (NMOSD) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics, TG Therapeutics, Bio-Thera Solutions, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorder (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorder (NMOSD).
The Neuromyelitis Optica Spectrum Disorder (NMOSD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Report

Report Metric Details
Report Name Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
Segment by Type
  • Intravenous
  • Oral
  • Subcutaneous
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics, TG Therapeutics, Bio-Thera Solutions, Boston Pharmaceuticals, Cour Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market report?

Ans: The main players in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market are F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics, TG Therapeutics, Bio-Thera Solutions, Boston Pharmaceuticals, Cour Pharmaceutical

What are the Application segmentation covered in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market report?

Ans: The Applications covered in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market report?

Ans: The Types covered in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market report are Intravenous, Oral, Subcutaneous, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Intravenous
1.2.3 Oral
1.2.4 Subcutaneous
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2020-2031)
2.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Region (2020-2025)
2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2026-2031)
2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics
2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Trends
2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2020-2025)
3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2020-2025)
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2024
3.5 Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD) Head office and Area Served
3.6 Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD), Product and Application
3.7 Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2020-2025)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2026-2031)
5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2020-2025)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2020-2031)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025)
6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2020-2031)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025)
7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2020-2031)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2020-2025)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2020-2031)
9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025)
9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2020-2031)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Details
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.1.5 F. Hoffmann-La Roche Ltd Recent Development
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Company Details
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.2.5 Alexion Pharmaceuticals Recent Development
11.3 RemeGen
11.3.1 RemeGen Company Details
11.3.2 RemeGen Business Overview
11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.3.5 RemeGen Recent Development
11.4 Nihon Pharmaceutical
11.4.1 Nihon Pharmaceutical Company Details
11.4.2 Nihon Pharmaceutical Business Overview
11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.4.5 Nihon Pharmaceutical Recent Development
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Details
11.5.2 Harbour BioMed Business Overview
11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.5.5 Harbour BioMed Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.6.5 Lundbeck Recent Development
11.7 Bionure
11.7.1 Bionure Company Details
11.7.2 Bionure Business Overview
11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.7.5 Bionure Recent Development
11.8 Opexa Therapeutics
11.8.1 Opexa Therapeutics Company Details
11.8.2 Opexa Therapeutics Business Overview
11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.8.5 Opexa Therapeutics Recent Development
11.9 TG Therapeutics
11.9.1 TG Therapeutics Company Details
11.9.2 TG Therapeutics Business Overview
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.9.5 TG Therapeutics Recent Development
11.10 Bio-Thera Solutions
11.10.1 Bio-Thera Solutions Company Details
11.10.2 Bio-Thera Solutions Business Overview
11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.10.5 Bio-Thera Solutions Recent Development
11.11 Boston Pharmaceuticals
11.11.1 Boston Pharmaceuticals Company Details
11.11.2 Boston Pharmaceuticals Business Overview
11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.11.5 Boston Pharmaceuticals Recent Development
11.12 Cour Pharmaceutical
11.12.1 Cour Pharmaceutical Company Details
11.12.2 Cour Pharmaceutical Business Overview
11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
11.12.5 Cour Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Alexion Pharmaceuticals
RemeGen, Ltd.
Nihon Pharmaceutical
Harbour Biomed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical
List of Tables
 Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Intravenous
 Table 3. Key Players of Oral
 Table 4. Key Players of Subcutaneous
 Table 5. Key Players of Others
 Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2020-2025)
 Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2026-2031)
 Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
 Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
 Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
 Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
 Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players (2020-2025)
 Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2024)
 Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD), Headquarters and Area Served
 Table 22. Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD), Product and Application
 Table 23. Global Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD), Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2020-2025)
 Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2026-2031)
 Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2020-2025)
 Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2026-2031)
 Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 48. F. Hoffmann-La Roche Ltd Company Details
 Table 49. F. Hoffmann-La Roche Ltd Business Overview
 Table 50. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 51. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 52. F. Hoffmann-La Roche Ltd Recent Development
 Table 53. Alexion Pharmaceuticals Company Details
 Table 54. Alexion Pharmaceuticals Business Overview
 Table 55. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 56. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 57. Alexion Pharmaceuticals Recent Development
 Table 58. RemeGen Company Details
 Table 59. RemeGen Business Overview
 Table 60. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 61. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 62. RemeGen Recent Development
 Table 63. Nihon Pharmaceutical Company Details
 Table 64. Nihon Pharmaceutical Business Overview
 Table 65. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 66. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 67. Nihon Pharmaceutical Recent Development
 Table 68. Harbour BioMed Company Details
 Table 69. Harbour BioMed Business Overview
 Table 70. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 71. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 72. Harbour BioMed Recent Development
 Table 73. Lundbeck Company Details
 Table 74. Lundbeck Business Overview
 Table 75. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 76. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 77. Lundbeck Recent Development
 Table 78. Bionure Company Details
 Table 79. Bionure Business Overview
 Table 80. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 81. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 82. Bionure Recent Development
 Table 83. Opexa Therapeutics Company Details
 Table 84. Opexa Therapeutics Business Overview
 Table 85. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 86. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 87. Opexa Therapeutics Recent Development
 Table 88. TG Therapeutics Company Details
 Table 89. TG Therapeutics Business Overview
 Table 90. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 91. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 92. TG Therapeutics Recent Development
 Table 93. Bio-Thera Solutions Company Details
 Table 94. Bio-Thera Solutions Business Overview
 Table 95. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 96. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 97. Bio-Thera Solutions Recent Development
 Table 98. Boston Pharmaceuticals Company Details
 Table 99. Boston Pharmaceuticals Business Overview
 Table 100. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 101. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 102. Boston Pharmaceuticals Recent Development
 Table 103. Cour Pharmaceutical Company Details
 Table 104. Cour Pharmaceutical Business Overview
 Table 105. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
 Table 106. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025) & (US$ Million)
 Table 107. Cour Pharmaceutical Recent Development
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Picture
 Figure 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2024 VS 2031
 Figure 4. Intravenous Features
 Figure 5. Oral Features
 Figure 6. Subcutaneous Features
 Figure 7. Others Features
 Figure 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Clinic Case Studies
 Figure 12. Others Case Studies
 Figure 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered
 Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region: 2024 VS 2031
 Figure 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2024
 Figure 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2024
 Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2020-2031)
 Figure 22. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2020-2031)
 Figure 26. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2020-2031)
 Figure 34. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2020-2031)
 Figure 42. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2020-2031)
 Figure 46. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 50. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 51. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 52. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 53. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 54. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 55. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 56. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 57. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 58. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 59. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 60. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2020-2025)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Neuromyelitis Optica Spectrum Disorders NMOSD Market Research Report 2024
Neuromyelitis Optic Spectrum Disorder Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuromyelitis Optica Drug Market Research Report 2025
Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030
Neuromyelitis Optica Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Neuromyelitis Optica Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metachromatic Leukodystrophy Treatment Market Research Report 2025
Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030
Multiple Sclerosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Demyelinating Diseases Therapeutics Market Research Report 2024
Transverse Myelitis Diagonosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurometabolic Disorders Market Insights Forecast to 2030
Global Chronic Fatigue Syndrome Treatment Market Insights Forecast to 2030
Global Optic Neuritis Drug Market Research Report 2025
Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Research Report 2024
Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Optic Nerve Disorders Treatment Market Insights Forecast to 2030

RELATED REPORTS

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13Z8760
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Intracranial Pressure (ICP) Monitoring Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37L4006
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Brain Disease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12P6151
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3X6389
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions